General | Syndax Pharmaceuticals, Inc.

Skip to main navigation

About Us
Focus Areas
Pipeline
Our Products
Patients
- Patients
- Managed Access Programs
Investors
Careers
News
Contact Us

Investors

Home
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Stock Information
Shareholder Services

code

General

Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

Read more about Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

Read more about Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

Syndax Announces Participation in March Investor Conferences

Read more about Syndax Announces Participation in March Investor Conferences

Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

Read more about Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

Read more about Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

Read more about Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Read more about Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Read more about Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

Read more about Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

Read more about Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

Pagination

Page 1
Next page

Subscribe to General

About Us
Focus Areas
Pipeline
Our Products
Patients
Investors
Careers
News
Contact Us

Privacy Notice

Cookie Notice

Consumer Health Data Supplemental Privacy Notice

State Regulations

Terms of Use

Limit the Use of My Personal Information

© 2026 Syndax Pharmaceuticals, Inc.

linkedin x.com glassdoor